Movement Alert｜3SBio Rises 5.1% in Regular Trading, SSGJ-707 Clinical Data Showcased at ASCO Annual Meeting

Market Focus05-29

On May 29, 3SBio rose 5.1% in regular trading, trading at HK$18.1/share, with trading volume of HK$252 million.

On the news front, the ASCO Annual Meeting officially opened today, with 3SBio's core pipeline PD-1/VEGF bispecific antibody SSGJ-707 having two clinical studies selected for presentation, including one receiving a rapid oral report. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In another Phase II study combining chemotherapy as first-line treatment for endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively.

The broader Biotechnology sector rallied in tandem, with Innovent Bio up 10.35%, Akeso up 7.16%, Remegen up 3.17%, PegBio up 1.93%, and BeiGene up 1.48%, reflecting strong sector-wide momentum that further boosted market sentiment around innovative drug names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103426751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103426751","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Rises 5.1% in Regular Trading, SSGJ-707 Clinical Data Showcased at ASCO Annual Meeting","media":"Market Focus","content":"<p><p>On May 29, 3SBio rose 5.1% in regular trading, trading at HK$18.1/share, with trading volume of HK$252 million.</p><p>On the news front, the ASCO Annual Meeting officially opened today, with 3SBio's core pipeline PD-1/VEGF bispecific antibody SSGJ-707 having two clinical studies selected for presentation, including one receiving a rapid oral report. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In another Phase II study combining chemotherapy as first-line treatment for endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively.</p><p>The broader Biotechnology sector rallied in tandem, with Innovent Bio up 10.35%, Akeso up 7.16%, Remegen up 3.17%, PegBio up 1.93%, and BeiGene up 1.48%, reflecting strong sector-wide momentum that further boosted market sentiment around innovative drug names.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Rises 5.1% in Regular Trading, SSGJ-707 Clinical Data Showcased at ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Rises 5.1% in Regular Trading, SSGJ-707 Clinical Data Showcased at ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, 3SBio rose 5.1% in regular trading, trading at HK$18.1/share, with trading volume of HK$252 million.</p><p>On the news front, the ASCO Annual Meeting officially opened today, with 3SBio's core pipeline PD-1/VEGF bispecific antibody SSGJ-707 having two clinical studies selected for presentation, including one receiving a rapid oral report. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In another Phase II study combining chemotherapy as first-line treatment for endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively.</p><p>The broader Biotechnology sector rallied in tandem, with Innovent Bio up 10.35%, Akeso up 7.16%, Remegen up 3.17%, PegBio up 1.93%, and BeiGene up 1.48%, reflecting strong sector-wide momentum that further boosted market sentiment around innovative drug names.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1103426751","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103426751","pubTimestamp":1780026644,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, 3SBio rose 5.1% in regular trading, trading at HK$18.1/share, with trading volume of HK$252 million.On the news front, the ASCO Annual Meeting officially opened today, with 3SBio's core...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"动向提示|三生制药常规交易涨5.1%ASCO年会展示SSGJ-707临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On May 29, 3SBio rose 5.1% in regular trading, trading at HK$18.1/share, with trading volume of HK$252 million.On the news front, the ASCO Annual Meeting officially opened today, with 3SBio's core pipeline PD-1/VEGF bispecific antibody SSGJ-707 having two clinical studies selected for presentation, including one receiving a rapid oral report. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In another Phase II study combining chemotherapy as first-line treatment for endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively.The broader Biotechnology sector rallied in tandem, with Innovent Bio up 10.35%, Akeso up 7.16%, Remegen up 3.17%, PegBio up 1.93%, and BeiGene up 1.48%, reflecting strong sector-wide momentum that further boosted market sentiment around innovative drug names.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103426751","isCrawlerRequest":true}